Press Needle Acupuncture for Pain and Quality of Life in Lung Cancer Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Press Needle Acupuncture and standart therapy.
- Who it may be relevant to
- Registry conditions: Lung Cancer Patients. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Indonesia
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Effect of Press Needle Acupuncture on Pain Reduction and Quality of Life Improvement in Lung Cancer Patients
Overview
The purpose of this clinical trial is to evaluate the effect of press needle acupuncture on pain management and quality of life improvement in patients with lung cancer. The main question this study aims to answer is: Does press needle acupuncture, when combined with standard therapy, provide better pain relief and quality of life improvement in lung cancer patients compared to standard therapy alone? Researchers will compare press needle acupuncture to sham acupuncture to determine whether press needle acupuncture is more effective in reducing pain and improving quality of life. Participants will: Receive either press needle acupuncture or sham press needle acupuncture for 7 days Visit the clinic once a week for examination and evaluation Record improvements in pain intensity in a pain diary and assess quality of life using a quality of life questionnaire
Interventions
- Device Press Needle Acupuncture and standart therapy
The patient will have a press needle applied, which will be removed on the seventh day.
Primary outcome measures
- Visual Analogue Scale (VAS) for Pain [Time frame: Before therapy, Day 1, Day 3, Day 7, and Day 14]
Secondary outcome measures (1)
- Functional Assessment of Cancer Therapy - Lung (FACT-L) [Time frame: Before therapy, Day 7, and Day 14]
Eligibility criteria
Inclusion criteria
- Patients with a confirmed diagnosis of lung cancer through histopathology or radiology.
- Lung cancer patients aged over 18 years.
- Stage III-IV lung cancer patients receiving therapy at Dr. Cipto Mangunkusumo National General Hospital (RSUPN) and Tangerang District General Hospital (RSUD Kabupaten Tangerang).
- Patients with a VAS score >10 mm for baseline pain and >40 mm during breakthrough pain.
- Willing to participate in the study until completion by signing the informed consent form.
Exclusion criteria
- Lung cancer patients with deteriorating general condition.
- Presence of wounds or infections at the press needle insertion site.
- History of allergy to stainless steel materials.
- Patients with blood clotting disorders: platelet count <50,000/μL, ANC <1000/mm³, or patients undergoing anticoagulant therapy with INR >2.142.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
Indonesia · 1 center
- Universitas Indonesia — Jakarta Pusat
Identifiers
NCT: NCT07112950 · 25-05-0758